Shopping Cart
- Remove All
- Your shopping cart is currently empty
Totrombopag, also known LGD-4665, GSK2285921 and SB559448, is an oral thromobopoietin receptor agonist, is being developed as a new generation small molecule thrombopoietin (TPO) mimetic. It is a highly selective and potent agonist of the TPO receptor and therefore induces differentiation and proliferation of megakaryocytes. The pharmacologic characteristics indicate potential therapeutic use in thrombocytopenic patients with a variety of clinical etiologies.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
25 mg | $1,970 | 8-10 weeks | |
50 mg | $2,580 | 8-10 weeks | |
100 mg | $3,400 | 8-10 weeks |
Description | Totrombopag, also known LGD-4665, GSK2285921 and SB559448, is an oral thromobopoietin receptor agonist, is being developed as a new generation small molecule thrombopoietin (TPO) mimetic. It is a highly selective and potent agonist of the TPO receptor and therefore induces differentiation and proliferation of megakaryocytes. The pharmacologic characteristics indicate potential therapeutic use in thrombocytopenic patients with a variety of clinical etiologies. |
Molecular Weight | 569.67 |
Formula | C30H35N9O3 |
Cas No. | 851606-62-7 |
Storage | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.